Quick Answer
Apyx Medical Corp reported R&D Expense of $3.37 million for fiscal year 2025.
Apyx Medical Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.37M | -33.6% |
| 2024 | $5.08M | -6.6% |
| 2023 | $5.44M | +19.7% |
| 2022 | $4.54M | +5.2% |
| 2021 | $4.32M | +10.2% |
| 2020 | $3.92M | +5.1% |
| 2019 | $3.73M | +46.4% |
| 2018 | $2.55M | +31.3% |
| 2017 | $1.94M | +87.9% |
| 2016 | $1.03M | -52.2% |
| 2015 | $2.16M | +52.5% |
| 2014 | $1.42M | +12.4% |
| 2013 | $1.26M | -5.2% |
| 2012 | $1.33M | +11.0% |
| 2011 | $1.20M | -35.4% |
| 2010 | $1.85M | -11.0% |
| 2009 | $2.08M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $801.0K | -29.9% | -2.8% |
| June 30, 2025 | $824.0K | -42.1% | +2.5% |
| March 31, 2025 | $804.0K | -42.4% | -29.6% |
| September 30, 2024 | $1.14M | -18.9% | -19.8% |
| June 30, 2024 | $1.42M | +4.9% | +1.9% |
| March 31, 2024 | $1.40M | +9.9% | -0.9% |
| September 30, 2023 | $1.41M | +32.8% | +3.8% |
| June 30, 2023 | $1.36M | +26.8% | +6.8% |
- Apyx Medical Corp showed a decrease of -33.6% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, Apyx Medical Corp’s r&d expense has grown by 61.9% (from $2.08 million to $3.37 million).
- The most recent figure is from Apyx Medical Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: